Can-Fite BioPharma
CANF----
Can-Fite BioPharma (CANF)
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cance...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Can-Fite BioPharma Analyst Rating
View MoreForecast & Rating
Jul 2, 2026Price forecast
$8.00150.78%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Unusual Whales · Jul 14 at 06:04 AM
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
- benzinga_article · Jul 2 at 12:05 PM
11 Health Care Stocks Moving In Thursday's Intraday Session
- businessinsider · Jul 2 at 04:30 AM
Biggest stock movers Thursday: FIZZ, CANF, and more
- WorldPharmaceuticals · Jul 2 at 04:22 AM
Can-Fite’s Namodenoson meets primary safety endpoints in Phase IIa trial
- rttnews · Jul 1 at 10:22 PM
Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watch
- US Stock Market Update · Jul 1 at 03:12 PM
Can-Fite BioPharma Soars 56% After Cancer Drug Trial Meets Safety Endpoint
